Note 14 - Net Loss Per Share - Antidilutive Securities Excluded from Computation (Details) - shares |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Antidilutive securities (in shares) | 10,707,008 | 7,527,524 | 10,707,008 | 7,527,524 |
| Convertible Notes Payable [Member] | ||||
| Antidilutive securities (in shares) | 1,209,289 | 62,500 | 1,209,289 | 62,500 |
| Common Stock Warrants [Member] | ||||
| Antidilutive securities (in shares) | 6,818,518 | 5,271,604 | 6,818,518 | 5,271,604 |
| Share-Based Payment Arrangement, Option [Member] | ||||
| Antidilutive securities (in shares) | 2,312,795 | 1,825,429 | 2,312,795 | 1,825,429 |
| Restricted Stock [Member] | ||||
| Antidilutive securities (in shares) | 36,778 | 38,363 | 36,778 | 38,363 |
| Contingent Earnout Shares [Member] | ||||
| Antidilutive securities (in shares) | 329,628 | 329,628 | 329,628 | 329,628 |